Drug-eluting stents: new era and new concerns.
At present there is much excitement about drug-eluting stents, which hold promise for the treatment of coronary artery disease. This ingenious therapy involves coating the outside of a standard coronary stent with a thin polymer containing medication that can prevent scarring at the site of coronary intervention. Early trials with sirolimus coated stents showed that they might prevent coronary artery restenosis, but later studies, involving more complex coronary lesions, did not show a complete absence of restenosis. Recent studies have demonstrated the long term cost effectiveness of drug-eluting stents as they have reduced the need for revascularisation procedures. At present there are few data on the safety and effectiveness of stents over follow up periods exceeding two years, and data obtained from animal models of stenting might not be completely applicable to humans. There are concerns that drug-eluting stents might delay, rather than inhibit, restenosis. Also there is concern regarding the inflammation caused by the polymer substrate. This article reviews the present data on drug-eluting stents and their benefits, shortcomings, and concerns.
Bhatia
V
V
Department of Internal Medicine, State University of New York, Buffalo, New York, USA. vbhatia@buffalo.edu
Bhatia
R
R
Dhindsa
M
M
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000191:economics / Q000517:prevention & control; D023921:Coronary Stenosis / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D004343:Drug Implants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects / Q000191:economics
D000972:Antineoplastic Agents, Phytogenic; D004343:Drug Implants; D017239:Paclitaxel